BRIM Biotech facilitated the enrollment for a Phase III clinical trial of their dry eye disease drug

撰文GlobalBio & Investment
日期2023-12-31
EnglishFrenchGermanItalianPortugueseRussianSpanish
BRIM Biotech facilitated the enrollment for a Phase III clinical trial of their dry eye disease drug
Dive into BRIM Biotechnology, Inc. 's translational medicine strategy that facilitated the enrollment for a Phase III clinical trial of their dry eye disease drug within ONE year! ✨

Discover more in-depth coverage here:
https://lnkd.in/guBmcNhq

Stay tuned to #globalbio for more updates!

#BRIMBiotech #ClinicalTrials #dryeyedisease #translationalmedicine